The incidence of liver failure following liver resection has been reported to be between 8-32%, depending on the number of segments resected, the health of the patient and the incidence of hepatic ischaemic/reperfusion injury. This article outlines the evidence surrounding classification, prevention and management of this condition.
Introduction
Mild liver dysfunction is occasionally seen following major surgery. Acute liver failure is much rarer. Patients at greatest risk of developing postoperative liver failure are those undergoing liver resection, where the risk can be as high as 32%. 1 When it does occur, acute liver failure is a devastating complication, with a high morbidity and mortality.
The spectrum of liver dysfunction post-hepatic resection encompasses everything from a transient rise in liver enzymes to fulminant liver failure and death. The features include coagulopathy, hyperbilirubinaemia, encephalopathy and associated multiple organ failure. The most effective way to reduce the impact of this complication is to prevent it developing in the first instance, which requires a careful and considered approach. Early identification of patients at risk and prompt and appropriate management of those developing acute liver failure is key.
The incidence of liver resection surgery is increasing as a treatment for certain benign and malignant liver lesions. The most common indication in the UK is for treatment of liver metastases associated with colorectal cancer. Approximately 3,600 patients per year fit into this category, a figure that will only increase with improvements in chemotherapy regimens. 2 Hepatic resection is also performed in live-donor liver transplantation.
This article reviews the management of post-hepatic resection liver failure, strategies for preventing it and some future directions in treatment.
Definition and incidence
Despite its potential severity, there is no universally accepted definition of postoperative liver failure 3 and therefore it is difficult to accurately determine its incidence. The International Study Group of Liver Surgery (ILSGLS) has recently produced this definition: 4 'a postoperative acquired deterioration in the ability of the liver to maintain its synthetic, excretory and detoxifying functions, which is characterised by an increased international normalised ratio and concomitant hyperbilirubinemia on or after postoperative day 5.' The group also differentiated the severity of postoperative liver failure into three different grades from A to C, depending on the level of treatment needed. Grade A encompasses development of abnormal blood tests but no change in clinical management; grade B suggests the degree of liver failure needed clinical management but not invasive therapy; grade C is acute postoperative liver failure requiring invasive treatment (see Table 1 ).
Other methods that have been used to define postoperative liver failure include the '50-50' criteria. 5 A serum bilirubin concentration above 50 µmol/L and a prothrombin time (PT) which is increased by more than 50% of baseline (or INR >1.7) on postoperative day five is associated with a mortality of 59% as opposed to 1.2% if these criteria are not met (sensitivity 69.6%, specificity 98.5%).
Another grading system 6 used to predict the risk of postoperative liver failure is demonstrated in Table 2 . Values should be present on two consecutive days during the postoperative course. Points score 0=no dysfunction, 1-2=mild,
Grade C
Post-hepatectomy liver failure resulting in a deviation from the regular clinical management and requiring invasive treatment Table 1 ISGLS consensus severity grading of post-hepatectomy liver failure. 4 3-4=moderate, >4= severe dysfunction. The incidence of acute liver failure following hepatic resection has been reported to be as high as 32% by some authors, 1 although others suggest it is nearer 8%. Schindl and colleagues believe that the risk should be quoted as less than 1% in patients with no parenchymal disease and having small resections; 10% when four segments are being resected and 30% for those having five or more segments resected. 6 With advances in surgical and anaesthetic techniques, mortality rates following liver resection surgery have decreased from 20% in the 1970s 8 to approximately 2% today. 9 Postoperative hepatic insufficiency/failure accounts for between 60 and 100% of these deaths. 5, 6, [10] [11] [12] Morbidity following liver resection remains high, with rates between 15-35%. [13] [14] [15] 
Causes of post-hepatic resection liver failure
Liver dysfunction is seen occasionally after any major surgery. Periods of intraoperative hypoxia, hypotension, the use of blood transfusions or development of sepsis can all result in liver ischaemia and/or cellular dysfunction. Following liver resection, intra-operative blood loss of more than one litre with the need for blood transfusion increases the risk of postoperative liver failure and sepsis. 16, 17 Sepsis has a detrimental effect on liver function (by inhibiting Kupffer cell function) and affects hepatic cell regeneration. 18 A normal subject with no other risk factors can have up to 75% of their liver resected safely. 19 The liver has a great capacity to regenerate, and the remnant can increase by 100% in size in as little as a week (although this is not reflected in a concomitant increase in synthetic function).
The most important risk factors for postoperative liver failure are: 3, 12 • The size of resection • Evidence of preoperative liver parenchymal disease (eg cirrhosis) • Hepatic ischaemia/reperfusion injury.
Removal of four or more segments (out of eight) is associated with an increased risk of postoperative liver failure. If the liver remnant is too small, there may not be enough functioning hepatocytes for adequate synthesis, excretion and detoxification. Another problem with small liver remnants is hyperperfusion; 20 the relative increase in blood flow causes sinusoidal dilatation, haemorrhagic infiltration, centrilobar necrosis and prolonged cholestasis, causing further impaired synthetic function and inhibition of cell proliferation. 3, 20 Underlying liver disease reduces the functional and regenerative capacity of the liver and therefore makes it more susceptible to damage. A larger remnant volume needs to be present at the end of surgery. 3, 18 Chemotherapy also affects liver parenchyma and reduces its regenerative capacity. A recent French study looked at 101 patients undergoing intensive chemotherapy (≥6 cycles of the newer chemotherapy agents: oxaliplatin and irinotecan) prior to undergoing liver resection. They found that 50% of patients developed sinusoidal obstruction syndrome and 10% steatohepatitis on histological analysis (5% had both). 20 Both sinusoidal injury and steatosis from chemotherapy reduce the regenerative capacity of the liver remnant and therefore increase the likelihood of postoperative failure. 3, 22, 23 Sinusoidal injury may also occur as a result from 'small-for-size syndrome,' when dysfunction occurs after a living-donor partial graft. It is thought to be due to portal hyperperfusion of the graft, combined with poor venous outflow, resulting in sinusoidal congestion and endothelial dysfunction. 24 A similar picture can be seen after extensive hepatic resection with a small liver remnant.
Vascular occlusive techniques used to reduce intraoperative bleeding comprise either total occlusion of both inflow and outflow, or total inflow occlusion. The 'Pringle' manoeuvre refers to the total occlusion of inflow, ie occlusion of hepatic artery and portal vein inflow to the liver. This limits blood supply to the liver, with the result that bleeding will principally be a result of hepatic venous pressure, which itself can be reduced by maintaining a low CVP intraoperatively. Occlusion induces ischaemia in the liver remnant, 25 resulting in hepatic ischaemia/reperfusion injury, the generation of free radicals and subsequent liver dysfunction. For this reason, the Pringle manoeuvre is now used much less frequently 26 and for less than forty-five minutes in total during surgery. 27 Other risk factors for postoperative liver failure include age over sixty-five, as the ability of the liver to regenerate decreases with age, 28 diabetes mellitus and poor nutritional status. 3, 18 Being male doubles the risk of developing postoperative liver failure. 29 Rarely, postoperative liver failure can result from altered vascular supply. Portal or hepatic vein obstruction can occur either through thrombosis, torsion or surgical injury. It is worth considering these options and excluding them with an ultrasound scan. Postoperative cholestasis can also 'muddy the waters.' It is often drug-induced (eg penicillin, erythromycin and NSAIDs), but can occasionally be a result of the surgery itself, or following total parenteral nutrition on the intensive care unit. Occasionally an isolated increase in bilirubin can occur, for example following a blood transfusion or in a patient with Gilbert' s syndrome. Gilbert' s syndrome is present in 2-5% of the population. A decreased activity of hepatic glucuronyl transferase leads to an increase in unconjugated bilirubin.
Preventative strategies Careful patient selection to ensure adequate residual liver volume
In patients with normal liver parenchyma, a remnant as small as 26% of the original liver' s volume can be safely left. 6 However those with parenchymal diseases require a larger residual volume (approximately 40%) to avoid postoperative liver failure; 19 a similar volume has been suggested for those patients who have received intensive chemotherapy treatment Total serum bilirubin (µmol/L) ≤20
21-60 >60
Prothrombin time <4 4 -6 >6 (seconds above normal)
Encephalopathy severity grade None 1 and 2 3 and 4 Table 2 Severity of postoperative hepatic dysfunction score. 6 (>6 cycles) prior to liver resection surgery. 21 In that study, the authors found that residual volumes of 44.8%, 43.1% and 37.7% were independent predictors of overall morbidity, sepsis and liver failure respectively. In patients with cirrhosis, resections should only be offered in those with stable disease (ie Child-Pugh class A); only very small resections in selected patients should be offered to patients with Child-Pugh class B, and avoided in class C patients.
Where an extensive resection is planned, avoiding the problems associated with a potentially small remnant can be achieved by employing strategies such as preoperative neoadjuvant chemotherapy to reduce the volume of tumour, performing a staged hepatectomy or a preoperative portal vein embolisation (PVE). PVE is one of the most useful strategies there is in preventing postoperative liver dysfunction and involves embolising one of the portal veins to induce liver atrophy on the operative side and hypertrophy in the intended remnant section. 30
Choice of anaesthetic agents
The volatile anaesthetic agents metabolised in the liver are known to alter hepatic blood flow and induce transient changes in liver enzymes. The use of halothane, which on repeated exposure may cause hepatitits (so-called 'halothane hepatitis') is now uncommon. Other volatile agents, including isoflurane, sevoflurane and desflurane, have minimal hepatic metabolism and there is a lack of evidence demonstrating hepatotoxicity. 31 Total intravenous anaesthesia (TIVA) has been advocated by some as a preferred option in liver surgery, but to date there is no evidence to support this.
Minimise blood loss
Postoperative blood transfusions have an immunosuppressive effect 16 and, as stated above, the requirement for blood transfusion following major blood loss increases the risk of postoperative liver failure. 16, 17 Strategies to reduce blood loss include: maintaining a low central venous pressure (<5 mm Hg), 32 avoidance of excessive PEEP, the use of thoracic epidurals, furosemide, and the use of GTN and remifentanil infusions. 33 Tranexamic acid is an anti-fibrinolytic that competitively inhibits the activation of plasminogen to plasmin and can be used to reduce intraoperative blood loss. Surgical techniques which can minimise blood loss include the use of the CUSA ™ (Cavitron Ultrasonic Surgical Aspirator), an ultrasonic system used to dissect liver parenchyma. It uses ultrasound at approximately 25 kHz, which has enough energy to destroy liver parenchyma but not enough to damage vascular structures. 36 Haemostatic agents have also been used to good effect. 37 They are applied directly onto the cut surface of the liver and contain granules of a gelatine matrix which promote the formation of a fibrin polymer from fibrinogen. Surgical use of the Pringle manoeuvre can also be used to prevent blood loss, but with the added risk of causing ischaemic damage.
Insulin therapy
Diabetes mellitus alters the immune response to surgery and increases morbidity and mortality after liver resection. 38, 39 High-dose insulin, combined with simultaneous preoperative oral carbohydrate loading and intravenous dextrose infusions, reduce the rates of postoperative liver dysfunction, infections and complications. 40 Fisette and colleagues used insulin infusions for all patients, (diabetics and non-diabetics), which led to higher cell substrate availability, altered the inflammatory response (decreased cytokines IL-6, IL-10, TNF-α and CRP) and decreased hepatocellular apoptosis. For these reasons, insulin and dextrose infusions have been used by some as treatment for postoperative liver dysfunction, 40 although there are no randomised controlled trials in this area.
Ischaemic preconditioning
Ischaemic preconditioning involves intermittent clamping of the portal triad and allows tolerance to a prolonged Pringle manoeuvre, resulting in less hepatic injury and dysfunction postoperatively, 41, 42 akin to cardiac pre-conditioning methods. The precise mechanism of this protection is unknown. Possible pathways involving roles for adenosine, protein kinase C, tyrosine kinases or nitric oxide have all been hypothesised. 43
Features of acute liver failure
Acute liver failure is characterised by a number of biochemical and haematological abnormalities, and widespread organ dysfunction.
Biochemistry
By definition, there is non-obstructive jaundice. Liver failure is commonly associated with a salt/water imbalance due to reduced renal blood flow and abnormalities that develop within the renin-angiotensin axis. There is a tendency towards water retention and hyponatraemia. A metabolic acidosis often develops in the early stages of acute liver failure. This can originate from a number of different sources. Lactic acid is poorly metabolised, inadequate tissue oxygen delivery (or use) can generate lactic acid, and associated acute kidney injury results in the presence of other organic acids. Hypoglycaemia develops from an impaired glycogenolysis and gluconeogenesis. Other electrolytes (Mg 2+ , K + , PO 4 3-) are often deranged and may need replacing.
Haematology
A coagulopathy invariably develops, including potentially low fibrinogen levels. There is decreased synthesis of clotting factors V, VII, IX and X that results in prolonged prothrombin and activated partial thromboplastin times. There will also be an element of fibrinolysis, such that bleeding can be worse than anticipated by the laboratory test results. Platelet numbers are often low, due to consumption within the damaged liver, and their function often impaired. Haemorrhage can develop from any site. Brain haemorrhage is a particularly devastating complication, while gastrointestinal bleeding is perhaps the most common. It may develop from stress gastritis, concomitant ulcers, and portal hypertensive gastropathy or varices, if present.
Neurology
Encephalopathy, cerebral oedema, intracranial haemorrhage and seizures are all recognised complications in acute liver failure. Intracranial haemorrhage should be suspected if there are localising signs. Cerebral oedema is a worrying complication, which is more prevalent the more acute the liver failure. Increased ammonia may be involved in the development of cerebral oedema by both cytotoxic and vasogenic mechanisms.
Cardiovascular
Distributive shock develops with severe peripheral shunting. A high cardiac output, decreased oxygen extraction, and low systemic vascular resistance are all features. The origin of the peripheral shunting is unclear. It may be the result of platelet/fibrin plugs, and abnormal vasomotor tone. 44 The result is poor peripheral extraction of oxygen.
Renal
Acute kidney injury is common. This is multifactorial; the common reasons are pre-renal renal failure and acute tubular necrosis. Hepato-renal syndrome (HRS) can occur in fulminant liver failure and is associated with high morbidity and mortality. 45 HRS is more typically associated with decompensated chronic liver disease, portal hypertension and spontaneous bacterial peritonitis. Differentiating HRS from prerenal failure that progresses to ATN can be difficult. Urine sodium analysis and microscopy can be helpful. HRS typically takes longer to resolve, if it does at all, being associated with greater than 50% mortality. When acute liver failure develops following a resection, it will be acute (within 28 days), so manifestations more commonly linked to chronic liver disease are less likely to be present, such as portal hypertension and tense ascites. However, if they occur (as the underlying architecture of the remaining liver may be compromised) then they should be managed appropriately. If tense ascites is present, then reducing intra-abdominal pressure can improve renal function. Hypophosphataemia can also sometimes be seen after liver resection due to increased renal excretion of phosphate.
Infection
Immunocompromise is a feature of acute liver failure 12 and consequently bacterial and fungal infections are more prevalent. Infection can also be harder to detect as there is a blunted systemic inflammatory response in this population. A high index of suspicion is required; for management, see below.
Pharmacology
A number of drugs are metabolised in the liver. This results in prolonged effects of sedation, certain neuromuscular blockers and a number of 'housekeeping' ICU drugs, eg omeprazole.
Supportive management of acute liver failure
In most centres, patients undergoing liver resection will be admitted to a level 2 bed for initial postoperative care. The majority of patients will pass through without complication. If acute liver failure develops, then supportive management ( Table 3) is required until either the liver regenerates, a treatable cause of the liver failure is established or (if appropriate) an orthotic liver transplant is performed.
Airway
Intubation will be required when the airway is no longer protected in grade 3/4 encephalopathy, or if the airway is compromised in another way.
Respiratory
Hypoxia may be a problem due to concomitant pneumonia, pulmonary oedema or pulmonary haemorrhage. Due to the concern over the possibility of cerebral oedema, PaCO 2 will have to be controlled tightly at 4.5-5 kPa and minimal achievable PEEP should be used.
Cardiovascular
Distributive shock usually develops and appropriate fluid loading and vasopressors will be needed. A cerebral perfusion pressure of 50-60 mm Hg will be required for neuroprotection.
Neurological
As previously stated, encephalopathy, cerebral oedema, intracranial haemorrhage and seizures can occur. In acute liver failure, the level of encephalopathy and degree of oedema are closely linked. If cerebral oedema is suspected, neuroprotective strategies should be implemented such as the aforementioned control of carbon dioxide levels and arterial blood pressure control. Other aspects include maintaining blood sugar levels of less than 10 mmol/L (avoiding hypoglycaemia), keeping the head up at 30 degrees and avoiding ties for the endotracheal tube. An intracranial pressure monitor may be inserted; however, risks of intracranial bleeding and infection are higher in the liver failure population. It can be a useful monitor provided that it is used to guide use of aggressive therapy, such as hypertonic saline to achieve a sodium level of 145-155 mmol/L, mannitol, cooling to 32-34 degrees or deep sedation to achieve burst suppression. Other monitors can also be used, such as the transcranial Doppler or jugular bulb oxygen saturation monitor, to guide therapy. Encephalopathy is typically graded from 0 to 4, and is thought to result from a number of metabolites not cleared by the liver; this improves as liver function returns. Administration of regular lactulose may be helpful. Seizures should be initially controlled with phenytoin and minimal doses of benzodiazepines (due to their prolonged action). An electroencephalogram may be required to prove termination of seizures if any doubt exists. The cause for the seizures should be established, including brain imaging.
Biochemistry
Bicarbonate infusions can be used, but often, renal replacement therapy is required to provide the appropriate support for acidosis, fluid and electrolyte control. Anticoagulation of the filter circuit may not be required or, depending on the platelet count, prostacyclin may be used.
Coagulopathy
In the early postoperative period, it is reasonable to treat an INR of >1.5. However, others suggest that it is not necessary to correct clotting abnormalities (provided there is no bleeding) unless invasive procedures are planned or the coagulopathy is profound. 2 In fulminant liver failure, coagulopathy can be profound (and resistant to Vitamin K). In this unit, we correct the coagulopathy if haemostasis is required or for interventional procedures. Fresh frozen plasma (FFP) and cryoprecipitate can be used, but give a significant volume load. Consequently, recombinant factor VIIa and fibrinogen concentrate can be useful. Early thrombocytopenia is often not corrected until levels are below 50 x 10 9 /L and haemostasis is a concern. Thrombocytopenia that develops later can have lower limits prior to correction. Platelet dysfunction can be quantified by using appropriate thrombo-elastogram preparations or platelet function analysers.
Renal dysfunction
Acute kidney injury should be managed by the three basic principles:
• Providing an adequate blood pressure • Optimal cardiac output with appropriate fluid loading • Avoiding nephrotoxic drugs. If severe liver failure develops, continuous haemofiltration is usually required for a number of reasons, most commonly, profound acidosis. It is not clear whether haemodiafiltration or high volume exchanges provide any significant survival advantage. If HRS is suspected, then there is limited evidence to suggest that terlipressin is a useful vasopressor and that albumin is a useful replacement fluid. 46 This can be 4.5% albumin if hypovolaemia is suspected and 20% albumin otherwise.
In the event of tense ascites, drainage should be performed to prevent a high intra-abdominal pressure, but it is unclear whether high-volume or low-volume ascites removal (with appropriate albumin replacement) is beneficial.
Infection
Patients with liver failure are at particular risk of developing sepsis due to a combination of immunoparesis, poor nutritional status and increased gut translocation. Sepsis can arise as a result of both bacterial and fungal pathogens (see Table 4 ). Some studies have demonstrated that prophylactic antibiotics can reduce the incidence of infective complications in patients with established postoperative liver failure, 3, 7, 47, 48 however they are not routinely recommended as they have not been shown to improve outcomes or survival. 3, 49, 50 Equally, some studies have suggested a role for routine antifungal prophylaxis, although conclusive evidence is lacking. 51
Problem
Management/Aim 
/Mg ++ )
Stress ulcer prophylaxis Start proton pump inhibitor Table 3 Goal directed therapy, adapted from: van den Broek, 48 Hammond. 3 Diagnosing sepsis in this population is difficult and regular surveillance cultures are recommended with an early escalation of antibiotic therapy and antifungals.
Nutrition
Poor nutritional status can affect outcome after major cancer surgery. 53 It is associated with an altered immune response and can reduce regeneration of liver cells. [54] [55] [56] Early enteral feeding can preserve the integrity of the gut barrier and so reduce postoperative infection rates. 57, 58 Those developing liver failure should have regular high-dose lactulose (start at 20 mL tds) to produce 3-4 soft stools per day.
N-acetylcysteine (NAC)
Glutathione is an anti-oxidant found in the liver and plays an important role in the cellular defence mechanisms against oxidative damage from free radicals. 59, 60 Glutathione is oxidised by oxygen-free radicals; its oxidised form is then reduced by NADPH (reduced nicotinamide adenine dinucleotide phosphate) forming an oxidation/reduction cycle that serves to 'mop up' harmful free radicals. During hypoxia, glutathione stores are consumed, which can add to oxidative injury on reperfusion. 61, 62 NAC is a precursor to glutathione and, when given as an infusion postoperatively, may reduce liver dysfunction. NAC also has an anti-inflammatory action inhibiting chemotaxis. This, in turn, decreases the generation of oxygen-free radicals by phagocytic cells. 63 In other nonparacetamol-induced causes of acute liver failure, both intravenous and oral NAC have been shown to improve transplant-free survival and appear safe and well tolerated. 64, 65 However, the evidence for the routine use of NAC to reduce ischaemia/reperfusion injury and prevent complications after major surgery is inconclusive. 62 Many units still use this as a routine therapy until normal liver function has returned. 35
Acute postoperative liver failure amenable to treatment
It is important to rule out any treatable cause of post-resection liver failure:
• Portal vein thrombosis: This will give rise to ischaemia and possible infarction. The diagnosis can be made using either ultrasound Doppler or CT scan. The debate over whether early postoperative portal vein thrombosis is best managed with surgical de-obstruction or anticoagulation remains unresolved. 24 • Venous outflow obstruction: Where this is due to rotation of the remnant liver segment, surgical intervention is indicated. There is also a role for endovascular stenting to improve venous outflow. 66 • 'Small-for-size' remnant: There is some evidence that patients with a small remnant and venous congestion secondary to relative hyperperfusion may be successfully managed by decreasing portal venous inflow through embolisation of the splenic artery as described in two case series. 67, 68 Surprisingly, neither of these reported any serious complications such as splenic infarction, but this was not been replicated in another, smaller case series. 69
Liver transplantation
Liver resection is often performed for the removal of metastatic malignancy and in these circumstances, consideration for liver transplant is often not appropriate. However, provided there are no contraindications, liver transplantation can be considered and has been successfully used as the treatment of postoperative liver failure. 24 The Milan criteria, developed in patients undergoing resections for hepatocellular carcinoma to help identify those suitable for transplantation, are as follows:
• Single lesion hepatocellular carcinomas of <5 cm or up to three lesions <3 cm • No extra-hepatic disease • No vascular invasion. 70 Van den Broek et al 48 suggested that if the patients had favourable tumour characteristics, they would consider transplantation. These included an R0 resection (ie complete resection of tumour), low T (ie small tumour size) and negative nodal spread.
Novel therapies Hepatocyte transplantation
Infusion of cryopreserved hepatocyte cells into the hepatic portal vein has shown encouraging results for genetic, metabolic liver conditions. Encapsulated hepatocytes have been transplanted intraperitoneally (thereby avoiding the need for immunosuppressive therapy) to help treat postoperative liver failure, but this technology is at an early experimental stage. 71
Ex vivo perfusion using porcine livers
This technique has been used, with limited success. 72 In a case series of four patients, there was an improvement in biochemical markers, but only one patient stabilised enough to receive a transplant and proceed to long-term survival.
Extracorporeal hepatic support devices
There are several liver-support devices available, using albumin-linked haemodialysis systems, eg MARS ® , Prometheus ® , or SPAD extracorporeal liver-assist devices using cryopreserved xenogeneic or human hepatocytes. These have been used as a bridge to transplantation. These devices lead to an improvement in biochemical numbers but there is no evidence that they result in clinical improvement. 1, 48, 73 Five patients with postoperative liver failure received MARS ® (Molecular Adsorbant Recirculating System). All showed improvement in biochemical markers but only one survived. 74 A similar but larger case series from Hong Kong showed similar improvements in biochemical markers and similar poor outcomes with a 72.2% 30-day mortality. 75 MARS ® uses an extracorporeal system where blood is dialysed against an albumin-enriched solution. It is similar to the Prometheus ®
Fungal Bacterial

Candidia albicans Escherichia coli Aspergillus Staphylococcus
Pseudomonas Table 4 Commonest pathogens in liver failure. 52 system, which also uses the principle of albumin dialysis, where lipophilic albumin-bound toxins (eg bilirubin, etc) are filtered and then adsorbed with a second circuit, to clean the albumin before being returned to the patient. SPAD is a Single-Pass Albumin Dialysis system which uses a similar circuit to MARS ® , except it uses normal machines and no perfusion pump systems, and uses a counter-current flow of albumin solution. Studies have shown that SPAD can achieve greater clearance of ammonia and bilirubin than MARS ® , although clearance of water-soluble substances was similar between the two methods. 76
Conclusion
Despite vast improvements in the perioperative care of patients undergoing liver resection surgery, there remains a significant risk of developing postoperative liver failure. Best estimates place the incidence at about 8%. Preoperative liver function and resection size are the most important factors in the risk associated with postoperative liver failure, although a number of pre-and peri-operative factors are also important, such as the presence of diabetes mellitus or the use of vaso-occlusive techniques. With advances in chemotherapy, patients who traditionally would not have been considered operable are becoming amenable to surgical treatment. Careful patient selection and optimisation, for example using portal vein embolisation, are important in reducing the incidence of postoperative liver failure. If acute liver failure occurs, then treatable conditions (such as segment torsion) should be considered and appropriate supportive care provided. Preventing and managing complications (commonly infective or haemorrhagic) are also an important aspect of care. Fulminant post-resection liver failure has a very poor prognosis, accounting for the majority of post-liver resection deaths.
